Caseware UK (AP4) 2024.0.164 2024.0.164 2024-09-302024-09-30212023-10-01falseSpecialist medical practice.falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 10951303 2023-10-01 2024-09-30 10951303 2022-10-01 2023-09-30 10951303 2024-09-30 10951303 2023-09-30 10951303 c:Director1 2023-10-01 2024-09-30 10951303 d:FurnitureFittings 2023-10-01 2024-09-30 10951303 d:FurnitureFittings 2024-09-30 10951303 d:FurnitureFittings 2023-09-30 10951303 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-10-01 2024-09-30 10951303 d:ComputerEquipment 2023-10-01 2024-09-30 10951303 d:ComputerEquipment 2024-09-30 10951303 d:ComputerEquipment 2023-09-30 10951303 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-10-01 2024-09-30 10951303 d:OwnedOrFreeholdAssets 2023-10-01 2024-09-30 10951303 d:ComputerSoftware 2024-09-30 10951303 d:ComputerSoftware 2023-09-30 10951303 d:CurrentFinancialInstruments 2024-09-30 10951303 d:CurrentFinancialInstruments 2023-09-30 10951303 d:Non-currentFinancialInstruments 2024-09-30 10951303 d:Non-currentFinancialInstruments 2023-09-30 10951303 d:CurrentFinancialInstruments d:WithinOneYear 2024-09-30 10951303 d:CurrentFinancialInstruments d:WithinOneYear 2023-09-30 10951303 d:Non-currentFinancialInstruments d:AfterOneYear 2024-09-30 10951303 d:Non-currentFinancialInstruments d:AfterOneYear 2023-09-30 10951303 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-09-30 10951303 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2023-09-30 10951303 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-09-30 10951303 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-09-30 10951303 d:ShareCapital 2024-09-30 10951303 d:ShareCapital 2023-09-30 10951303 d:RetainedEarningsAccumulatedLosses 2024-09-30 10951303 d:RetainedEarningsAccumulatedLosses 2023-09-30 10951303 c:OrdinaryShareClass1 2023-10-01 2024-09-30 10951303 c:OrdinaryShareClass1 2024-09-30 10951303 c:OrdinaryShareClass1 2023-09-30 10951303 c:FRS102 2023-10-01 2024-09-30 10951303 c:AuditExempt-NoAccountantsReport 2023-10-01 2024-09-30 10951303 c:FullAccounts 2023-10-01 2024-09-30 10951303 c:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 10951303 6 2023-10-01 2024-09-30 10951303 e:PoundSterling 2023-10-01 2024-09-30 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 10951303









RACARDIOLOGY LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 SEPTEMBER 2024

 
RACARDIOLOGY LIMITED
REGISTERED NUMBER: 10951303

STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 5 
14,219
15,616

Investments
  
50,000
-

  
64,219
15,616

Current assets
  

Debtors: amounts falling due within one year
 7 
382,005
219,222

Cash at bank and in hand
 8 
169,313
254,599

  
551,318
473,821

Creditors: amounts falling due within one year
 9 
(41,134)
(22,192)

Net current assets
  
 
 
510,184
 
 
451,629

Total assets less current liabilities
  
574,403
467,245

Creditors: amounts falling due after more than one year
 10 
(3,630)
(6,925)

  

Net assets
  
570,773
460,320


Capital and reserves
  

Called up share capital 
 12 
100
100

Profit and loss account
  
570,673
460,220

  
570,773
460,320


Page 1

 
RACARDIOLOGY LIMITED
REGISTERED NUMBER: 10951303
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 SEPTEMBER 2024

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 23 June 2025.




Dr R Assomull
Director

Page 2

 
RACARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

1.


General information

RaCardiology Limited is a private company limited by shares and incorporated in England and Wales (registration no: 10951303). The registered office is 101 New Cavendish Street, 1st Floor South,  London, W1W 1XH.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

In assessing the ability of the company to operate as a going concern, management have evaluated current and forecasted operational results, and the solvency of the company. As a result, the director considers it appropriate to prepare the financial statements on a going concern basis.
Accordingly the director has continued to prepare the financial statements on the going concern basis.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
RACARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

2.Accounting policies (continued)

 
2.4

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


 
2.6

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
RACARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

2.Accounting policies (continued)


2.7
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures and fittings
-
25%
Straight line method
Computer equipment
-
25%
Straight line method

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.8

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Statement of Comprehensive Income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.9

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.10

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2023 - 2).

Page 5

 
RACARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

4.


Intangible assets




Computer software

£



Cost


At 1 October 2023
21,873



At 30 September 2024

21,873



Amortisation


At 1 October 2023
21,873



At 30 September 2024

21,873



Net book value



At 30 September 2024
-



At 30 September 2023
-



Page 6

 
RACARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

5.


Tangible fixed assets





Fixtures and fittings
Computer equipment
Total

£
£
£



Cost or valuation


At 1 October 2023
1,198
17,179
18,377


Additions
1,399
2,448
3,847



At 30 September 2024

2,597
19,627
22,224



Depreciation


At 1 October 2023
225
2,537
2,762


Charge for the year on owned assets
562
4,681
5,243



At 30 September 2024

787
7,218
8,005



Net book value



At 30 September 2024
1,810
12,409
14,219



At 30 September 2023
973
14,642
15,615


6.


Fixed asset investments





Unlisted investments

£



Cost or valuation


Additions
50,000



At 30 September 2024
50,000





7.


Debtors

2024
2023
£
£


Trade debtors
22,475
45,175

Other debtors
310,171
148,568

Prepayments and accrued income
49,359
25,479
Page 7

 
RACARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

7.Debtors (continued)


382,005
219,222



8.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
169,313
254,599

169,313
254,599



9.


Creditors: Amounts falling due within one year

2024
2023
£
£

Bank loans
3,295
3,229

Corporation tax
28,783
10,941

Other taxation and social security
373
1,403

Other creditors
3,992
1,509

Accruals and deferred income
4,691
5,110

41,134
22,192



10.


Creditors: Amounts falling due after more than one year

2024
2023
£
£

Bank loans
3,630
6,925

3,630
6,925


Page 8

 
RACARDIOLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

11.


Loans


Analysis of the maturity of loans is given below:


2024
2023
£
£

Amounts falling due within one year

Bank loans
3,295
3,229


3,295
3,229

Amounts falling due 1-2 years

Bank loans
3,363
6,658


3,363
6,658

Amounts falling due 2-5 years

Bank loans
267
267


267
267


6,925
10,154



12.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



100 (2023 - 100) Ordinary shares of £1.00 each
100
100


 
Page 9